Back to News
Market Impact: 0.2
Celldex Therapeutics Reports Third Quarter 2026 Financial Results
Source: Nasdaq
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Celldex Therapeutics reported a third-quarter 2026 net loss of $75.6 million, or $0.96 per share, compared with a $67.0 million net loss, or $1.01 per share, in the comparison period. The net loss increased, while the loss per share narrowed; the supplied article text does not specify the comparison period or provide further results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
-0.10
Ticker Sentiment
CLDX-0.10
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- AI stocks hammered by midterm shock as data center buildout becomes a 'war of attrition'
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FTSE 100 today: Stocks slump as global tech rout deepens